Tatton Consulting supported South Cambridgeshire-based women’s health technology company Tuune in its successful application to Biomedical Catalyst 2022 Round 2: Industry-led R&D, awarded £424,175 by Innovate UK for the project Improving NHS perimenopausal diagnosis and HRT prescription through AI, machine learning and big data.
About the funded R&D project
In October 2022 the all-party parliamentary group on menopause called for earlier screening, better training for health workers and improved access to treatment. This project applies AI, machine learning and biomarkers to perimenopausal diagnosis and HRT prescription, addressing the diagnostic step that currently delays treatment by years.
Award details
- Total project grant: £424,175
- Of which to Tuune: £419,753
- Competition: Biomedical Catalyst 2022 Round 2: Industry-led R&D
- Competition year: 2022/23
- Project: Improving NHS perimenopausal diagnosis and HRT prescription through AI, machine learning and big data
- Sector: Women’s health / AI diagnostics
- UKRI project record: Gateway to Research, project 10053966
- Dataset: Innovate UK funded projects, published 10 August 2026
Tatton Consulting supported the competitive grant application. The award value, competition and project title are taken from UKRI’s published record for this project.
See all Innovate UK awards Tatton Consulting has supported on our grant successes page.
